commons; compounded medication; drug research and development; intellectual property; open science; orphan drugs; point of care manufacturing; rare diseases
Résumé :
[en] Regulatory agencies installed orphan drug regulations to stimulate research and development of new innovative treatments for life-threatening diseases with a low prevalence (rare diseases). We established a list of well-known food-related ingredients with clinical evidence for rare diseases in the open medical literature that obtained marketing authorization as an expensive "orphan drug", protected by intellectual property (IP) rights. We show that these ingredients are part of an established practice of medicinal compounding-a form of point of care manufacturing. We argue that these ingredients should be considered as "pharmaceutical commons", and that regulatory incentives for private companies and market protection mechanisms such as IP rights are not justified in this case.
Bountra C., Lee W. H., Lezaun J., (2017). A New Pharmaceutical Commons: Transforming Drug Discovery. Oxford: Oxford Martin Policy Paper, 1–28.
Davies E. H., Fulton E., Brook D., Hughes D. A., (2017). Affordable Orphan Drugs: a Role for Not-for-profit Organizations. Br. J. Clin. Pharmacol. 83, 1595–1601. 10.1111/bcp.13240
Dooms M., Carvalho M., (2018). Compounded Medication for Patients with Rare Diseases. Orphanet J. Rare Dis. 13, 1. 10.1186/s13023-017-0741-y
Dooms M., Pincé H., Simoens S., (2013). Do we Need Authorized Orphan Drugs when Compounded Medications Are Available?. J. Clin. Pharm. Ther. 38, 1–2. 10.1111/jcpt.12006
European Commission (2021b). Food Additives. Available at: https://webgate.ec.europa.eu/foods_system/main/?sector=FAD&auth=SANCAS (Accessed July, 2021)
European Commission (2021a). Public Health - Union Register of Medicinal Products. Available at: https://ec.europa.eu/health/documents/community-register/html/index_en.htm (Accessed July, 2021)
European Medicines Agency (2021b). European Public Assessment Report. Available at: https://www.ema.europa.eu/en/glossary/european-public-assessment-report (Accessed July, 2021)
European Medicines Agency (2021a). Orphan Designation: Overview. Available at: https://www.ema.europa.eu/en/human-regulatory/overview/orphan-designation-overview (Accessed August, 2021)
Hendrickx K., (2019). The Political Space between Words and Things: Health Claims as Referential Displacement. Sci. as Cult. 28 (4), 427–448. 10.1080/09505431.2018.1557629
Huyard C., (2009). How Did Uncommon Disorders Become 'rare Diseases'? History of a Boundary Object. Sociol. Health Illn 31 (4), 463–477. 10.1111/j.1467-9566.2008.01143.x
Lezaun J., Montgomery C. M., (2015). The Pharmaceutical Commons: Sharing and Exclusion in Global Health Drug Development. Sci. Technol. Hum. Values 40 (1), 3–29. 10.1177/0162243914542349
Mikami K., (2017). Orphans in the Market: the History of Orphan Drug Policy. Soc. Hist. Med. 32 (3), 609–630. 10.1093/shm/hkx098
Ostrom E., (1990). Governing the Commons. The Evolution of Institutions for Collective Action. Cambridge: Cambridge University Press.
Picavet E., Dooms M., Cassiman D., Simoens S., (2011). Drugs for Rare Diseases: Influence of Orphan Designation Status on price. Appl. Health Econ. Health Pol. 9 (4), 275–279. 10.2165/11590170-000000000-00000
Rubinstein Y. R., Robinson P. N., Gahl W. A., Avillach P., Baynam G., Cederroth H., et al. (2020). The Case for Open Science: Rare Diseases. JAMIA Open 3, 472–486. 10.1093/jamiaopen/ooaa030
Simoens S., Cassiman D., Picavet E., Dooms M., (2011). Are Some Orphan Drugs for Rare Diseases Too Expensive? A Study of purchase versus Compounding Costs. Drugs Ther. Perspect. 27, 24–26. 10.2165/11601640-000000000-00000
Tambuyzer E., Vandendriessche B., Austin C. P., Brooks P. J., Larsson K., Miller Needleman K. I., et al. (2020). Therapies for Rare Diseases: Therapeutic Modalities, Progress and Challenges Ahead. Nat. Rev. Drug Discov. 19 (2), 93–111. 10.1038/s41573-019-0049-9
The Merck Index (2021). The Merck Index* Online. Available at: https://www.rsc.org/merck-index.
World Health Organization (2021). ATC/DDD Index. Available at: https://www.whocc.no/atc_ddd_index/(Accessed July, 2021).
